LABU250117C93500
- 0.24
- 0.000.00%
Direxion Daily S&P Biotech Bull 3x Shares ETF Newsroom
Natera To Provide Roadmap And Outlook At J.P. Morgan Healthcare Conference
Sarepta, Biogen Drugs With Accelerated Approval Under Fire in FDA Report
The Momentum Factor ETF Is Coming off a Great 2024 but Still Oversold
10 Health Care Stocks With Whale Alerts In Today's Session
AbbVie Goes Ex Dividend Tomorrow
JMP Securities Reiterates Market Perform on Incyteto Market Perform
Incyte At JPM25: Eyes Transformational 2025 With Multiple Drug Launches And Expanding Pipeline
Needham Reiterates Buy on Sarepta Therapeutics, Maintains $202 Price Target
Sarepta Therapeutics Analyst Ratings
On the first day of the JPM Medical Conference, pharmaceutical giants are announcing new strategies. Could the mergers and acquisitions in Biomedical begin in 2025?
In 2025, the Biomedical mergers and acquisitions will begin.
12 Health Care Stocks Moving In Monday's Pre-Market Session
Dow, S&P, Nasdaq Ended Trading Mixed Ahead of Inflation and Earnings Figures
Stocks Edge Down Ahead Of Key Inflation Reports, Crude Hits 5-Month High, Bitcoin Sinks: What's Driving Markets Monday?
Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge
Sarepta Announces Q4 2024 Revenue Of $638.2M, Exceeding Guidance; ELEVIDYS Revenue At $384.2M; RNA PMO Revenue At $254M; FY24 Revenue Totals $1.79B; $1.5B In Cash And Investments At Year-End 2024; Reiterates 2025 Revenue Guidance Of $2.9B-$3.1B
Crude Oil Surges 3%; Abercrombie & Fitch Shares Plunge
The Top and Bottom Contributors to S&P 500's Q4 EPS Growth
Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal
Moderna's stock price plummeted 20% in early trading! Sales of two flagship products were disappointing, leading to a significant cut in the annual revenue forecast.
① The American vaccine manufacturer Moderna expects revenue for 2025 to be between 1.5 billion and 2.5 billion USD due to a slowdown in demand for its two main products, which is significantly lower than the previously expected 2.5 billion to 3.5 billion USD; ② Moderna's stock price fell 20% due to the lowered revenue expectations, with its CEO stating that the adjustment reflects increased competition in the COVID-19 vaccine market, delayed infrastructure development, and a decline in vaccination rates.
Natera Shares Are Trading Higher After JP Morgan Upgraded the Stock From Underweight to Neutral and Raised Its Price Target From $40 to $50.